ASTRAZEN

What AstraZeneca Pharma India promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q1 FY26

what the last two calls moved 8 tracked 2 delivered 3 missed 3 open
  • Dividend Payout Ratio delivered said Q4 FY22 Promised: Increase towards 50% Q1 FY26: Company declared a dividend of ₹32 per share on an EPS of ₹46.3, resulting in a payout ratio of 69.1%, significantly exceeding the 50% mark.
  • Long-term Revenue went quiet said Q4 FY21 Promised: $1 billion by FY30 Q1 FY26: An analyst references the past 'billion dollar' vision, but management does not confirm, update, or recommit to this specific target.
  • Asset Sale at risk said Q1 FY25 Promised: Completion of sale in next 12 to 15 months Q1 FY26: Twelve months after the promise, management discusses costs related to the plant closure but does not confirm the completion of the sale or the realization value. The deadline is at risk.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 8 tracked commitments for AstraZeneca Pharma India — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens